We previously described a simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method to determine relative plasma exposures of drug metabolites across species for metabolite safety assessments. It offers time-and resource-sparing advantages to ascertain metabolite exposure comparisons between humans and laboratory animal species for stable metabolites with high confidence. In this study, we tested the limitation of the methodology with compounds possessing six substituents found in unstable metabolites. Stabilization procedures were used, and stabilized samples were compared with untreated samples for structures with established stabilization processes. In most cases, the parent compounds with established stability were used as the intrinsic stability references except in cases in which the metabolite was more stable than the parent compound. Long-term storage stability of the unstable structures was tested by comparing the response ratio of the metabolite to the stability reference compound for multiple independent analyses covering the storage duration. Autosampler stability was tested using the same response ratio of the reinjections of the reconstituted solution overnight over the first injections. The results supported that the possibility that an abbreviated LC-MS/MS peak area ratio comparison can be applied to epoxide, amide, catechol, and acyl glucuronides to determine the relative plasma exposure of drug metabolites across species; but it may not be suitable for iminium ions and esters. Stability of suspected unstable metabolites can be tested using the methodology described above.
Introduction
Toxicology studies conducted in laboratory animals are an essential component of human risk assessment for new drug candidates. In several studies, there has been a focus on ensuring the safety not only of the drug itself but also of the circulating metabolites (Luffer-Atlas, 2008; Robison and Jacobs, 2009; Smith and Obach, 2009; Anderson et al., 2010; Frederick and Obach, 2010) , which was triggered by a position offered by scientists from a pharmaceutical industry trade organization (Baillie et al., 2002) . Many articles have been published, laying out various strategies for incorporating an assessment of human circulating metabolites (i.e., prediction and identification) (Leclercq et al., 2009; Nedderman, 2009; Walker et al., 2009; Nedderman and Wright, 2010 ) that can be used in determining whether further examination of safety attributes of metabolites is warranted. Although there has not been perfect agreement among all discussants on this topic, regulatory guidance documents have been issued by the International Conference on Harmonization as well as by the U.S. Food and Drug Administration in which guidelines defining the thresholds for when human circulating metabolites merit further consideration in risk assessment have been outlined. The International Conference on Harmonization guidance states that human circulating metabolites that comprise 10% or more of total drug-related material in circulation should also be present in equivalent or greater concentrations in at least one of the laboratory animal species that are used in toxicology studies. It is important to note that the most reliable means by which it can be determined that a metabolite truly exceeds 10% of total drug-related material is through analysis of data from a 14 C (or in some cases tritium) human metabolism study. Such an approach offers the only means by which it can be assured that all drug-related material has been accounted for in a complex biological matrix. Measurements can be made using radiometric approaches, or if a determine the percentages of each metabolite because of differences in ionization efficiencies among the parent drug and various metabolites.
Demonstrating that a human circulating metabolite is present in larger quantities in toxicology species can pose a large resource burden in obtaining qualified authentic standards of metabolites (which frequently can be challenging to synthesize because of structural complexity) and developing validated bioanalytical methods to measure multiple metabolites simultaneously. To this end, investigators have proposed abbreviated approaches that can yield valuable information regarding relative exposures in animals and humans without the investment in generating an authentic standard or developing a bioanalytical method (Gao and Obach, 2011; Ma and Chowdhury, 2011) . Others have proposed use of quantitative NMR or use of radiometric calibration standards to make estimates of metabolite concentrations in plasma samples (Espina et al., 2009; Yi and LufferAtlas, 2010; Zgoda-Pols et al., 2010) .
Because the guidance documents state that it is important that animals contain higher concentrations of human circulating metabolites but do not specifically require a particular multiple, we designed and tested an approach whereby it could be determined which species has a higher concentration (Gao et al., 2010) . In this method, human and animal plasma samples containing unknown concentrations of drugs and metabolites are mixed with control plasma from the opposite species to yield samples of identical matrix. These are then processed and injected onto the HPLC-MS system with monitoring of the ion counts for the various metabolites of interest. The peak responses are compared across species, and it was shown that if an animal has twice the ion count response as a human, then it can be concluded that the animal has an equivalent or greater exposure to the metabolite. Only if the cross-species response ratio is within 2-fold would there be a need to develop a standard analytical method for the metabolite and measure the concentration more precisely. To our knowledge, this is the most resource-sparing approach that can provide assurance that animals receiving the parent drug during toxicology studies were exposed to metabolites relevant to humans. However, a potential shortcoming of this approach is that if a metabolite were unstable in plasma or during sample workup or if it had differing stability in animal versus human plasma when stored frozen, then an erroneous conclusion regarding relative exposures in humans versus animals could be made. In the absence of an authentic standard of a metabolite, quality control samples cannot be prepared and used in assessments of storage and processing stability. It has been shown that stability of metabolites, even in the absence of an authentic standard can be assessed using radiolabeled parent drug and biologically generated metabolites (Zgoda-Pols et al., 2010) ; however, this method still has the disadvantage of requiring radiolabeled material.
In this report, we applied our previously described metabolite peak area comparison approach to a set of six pairs of compounds possessing substituents that are also associated with chemical and/or enzymatic stability issues in plasma. The six included acyl glucuronide, catechol, ester, amide, epoxide, and iminium ion substituents. Rat and human plasma samples were spiked with known concentrations of these metabolites, and the peak area approach was applied in a blinded fashion to determine how closely the measured ratios matched the nominal values. The relationship between the measured peak area ratio values and storage time was also examined.
Materials and Methods
Chemicals and Reagents. HPLC-grade water was purchased from Mallinckrodt Baker, Inc. (Phillipsburg, NJ). ACS reagent-grade acetonitrile was purchased from Honeywell Burdick and Jackson (Muskegon, MI). Naproxen acyl glucuronide conjugate and N-acetyl sulfadiazine were purchased from Toronto Research Chemicals Inc. (Toronto, ON, Canada) . Naproxen, carbamazepine, carbamazepine-10,11-epoxide, sulfadiazine, salicylic acid, 2,3-dihydroxybenzoic acid, ascorbic acid, citric acid, cotinine, and methylphenidate were purchased from Sigma-Aldrich (St. Louis, MO). Ritalinic acid was purchased from Isotec International, Inc. (Canton, GA). Nicotine iminium ion diperchlorate was synthesized using methods described previously (Peterson et al., 1987) . Plastic plasma tubes with glycolytic inhibitor, 5.0 mg of NaF, and 4.0 mg of potassium oxalate were purchased from BD (Franklin Lakes, NJ). Wistar Hanover rat and human K 3 EDTA plasma were purchased from Bioreclamation, Inc. (Westbury, NY) except that the blank plasma samples for the nicotine iminium ion and cotinine analyses were collected in-house.
Sample Preparation. To test the limit of our simple LC-MS/MS methodology, pairs of drugs and their unstable metabolite were spiked into Wistar Hanover rat and human plasma samples. This was done for seven drugmetabolite combinations, and each combination was spiked in rat or human plasma to generate four different sample sets to cover a range of ratios that may be produced in actual samples. (The concentrations of individual analytes are listed in Supplemental Table 1 .) For some drugs, untreated plasma samples and stabilized samples using established stabilization procedures were generated in parallel. Naproxen and naproxen acyl glucuronide conjugate combinations were treated with 5% 2 M citric acid (v/v) to bring down the pH to 3.5; methylphenidate and ritalinic acid combinations were treated with 5.0 mg of NaF and 4.0 mg of potassium oxalate per 4 ml of plasma; salicylic acid and 2,3-dihydroxybenzoic acid combinations were treated with 5% of 500 mg/ml citric acid and 40 mg/ml ascorbic acid in plasma with the final pH between 3.5 and 5. All samples were stored at Ϫ20°C for long-term sample storage. Three independent analyses of each combination were performed to evaluate the long-term stability during sample storage. The samples and the molecular weights of the drugs and metabolites were provided to the bioanalytical chemist, but she was blinded to the parent and metabolite concentrations.
All samples were thawed at room temperature and then were kept on wet ice during sample preparation. Samples were mixed with an equivalent volume of blank plasma of the opposite species and diluted in mixed blank plasma as in previous work (Gao et al., 2010) . All samples were then prepared for LC-MS/MS analysis by the addition of 4 volumes of 100 ng/ml sulfadimethoxine in acetonitrile as an internal standard (IS) and protein precipitation reagent except for the naproxen-naproxen acyl glucuronide conjugate plasma samples for which 0.1% formic acid was added to the IS solution to stabilize the glucuronide conjugate. All samples were centrifuged, and the supernatants were dried under nitrogen and reconstituted with 20 l of acetonitrile with 0.1% formic acid followed by 180 l of water with 0.1% formic acid for sample analysis except that methylphenidate-ritalinic acid combinations were reconstituted using acetonitrile and water without formic acid and cotininenicotine iminium ion combinations were reconstituted in 100% water. Reinjection of the reconstituted solution was performed to evaluate the autosampler stability.
Liquid Chromatographic and Mass Spectrometric Methods. All sample analysis was performed on an API-5500 QTRAP triple quadrupole-linear ion trap mass spectrometer equipped with a Turbo V IonSpray ionization source, and all instrumentation control and quantitation was through the mass spectrometer Analyst software package (Applied Biosystems, Foster City, CA). The HPLC system consisted of two Prominence LC-AD10 components (Shimadzu, Columbia, MD). The autosampler was a CTC Analytics PAL autosampler (CTC Analytics AG, Zwingen, Switzerland) with temperature controlled at 11°C. Chromatographic separation was performed on a Phenomenex Kinetex C18 column (2.6 m, 75 ϫ 3.0 mm; Phenomenex, Torrance, CA), and the mobile phase consisted of two solvents, solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile) for all samples except the nicotine iminium ion-cotinine combination. The following gradient conditions (LC1 in Table 1 ) were used for naproxen-naproxen acyl glucuronide, carbamazepine-carbamazepine-10,11-epoxide, sulfadiazine-N-acetyl sulfadiazine, and methylphenidate-ritalinic acid: 0 to 3 min, 2% B; 3 to 33 min, 2 to 80% B; 33 to 36 min, 80 to 98% B; 36 to 38 min, 98% B; 38 to 41 min, 98 to 2% B, and 41 to 45 min, 2% B. The gradient conditions (LC2 in Table 1) were modified for salicylic acid-2,3-dihydroxybenzoic acid as follows: 0 to 3 min, 2% B; 3 to 23 min, 2 to 40% B; 23 to 36 min, and 40 to 98% B; gradient conditions from 36 to 45 min were the same as those listed above for LC1. The LC separation (LC3 in Table 1 ) for nicotine iminium ion-cotinine samples was performed on a Synergi Polar RP C18 column (4 m, 75 ϫ 3.0 mm; Phenomenex), and mobile phase A was 10 mM ammonium formate with 0.1% formic acid and mobile phase B was 100% acetonitrile. The LC gradients were the following: 0 to 5 min, 2% B; 5 to 23 min, 2 to 30% B; 23 to 28 min, 30 to 90% B; 28 to 32 min, 90% B; 32 to 36 min, 90 to 2% B; and 36 to 45 min, 2% B. The total run time of each injection for all LC methods was 45 min. A VICI valve (Valco Instruments Co., Houston, TX) was used to divert the first 0.5 min and the last 7 min of HPLC effluent to waste. The injection volume was 10 l.
For each analyte-metabolite combination, the analyte ionization parameters were optimized by infusing solutions of the parent drugs and internal standard in 50:50 0.1% formic acid in water-acetonitrile. Ionization and mass-dependent parameters for the parent drugs were used for their metabolites; the source temperature was set at 500°C except for the naproxen acyl glucuronide conjugate for which the source temperature was lowered to 400°C. The internal standard was monitored at the MRM transition of m/z 311 3 m/z 155 in positive ion mode and m/z 309 3 m/z 122 in negative ion mode.
An information-dependent acquisition method was used to trigger the collection of enhanced production scans for method development and qualitative identification of the metabolites. The first experiment of the mass spectrometer was set in the MRM (parent) or MIM (metabolite) mode for test sets. Detection of an ion signal greater than 5000 cps then triggered collisionally activated enhanced production (EPI) scans to generate structurally specific dissociation of the ion. EPI spectra were collected for three consecutive scans followed by an EPI scan mode exclusion time of 1 s. The parent ion for the IS was listed in the information-dependent acquisition exclusion list across the full LC run. The EPI scan was operated at a scan rate of 10,000 atomic mass units/s using the dynamic fill option in the linear ion trap. The collision energy was set at 50 eV (Ϫ50 eV for naproxen samples) with a spread of 40 eV. The dwell time for each MIM/MRM transition was 20 ms, and the total cycle time was approximately 0.2 s.
MIM_EPI and MRM_EPI for Qualitative Identification and Quantitation of Metabolites. The methodology for structural confirmation of the metabolites and selecting suitable daughter ions of the metabolites to achieve optimal sensitivity and selectivity for quantitation was described in previous work (Gao et al., 2010) .
Chromatographic peaks were integrated, and peak area ratios of metabolites versus the internal standard at the MRM transitions were calculated. Direct comparisons of metabolites in rat versus human plasma were achieved by calculating the rat/human ratio of these peak area ratios. To monitor the long-term storage and autosampler stability, a known stable compound was selected and served as the "intrinsic stability reference" compound in the plasma samples. The parent drug served this purpose for all the drugmetabolite combinations except that ritalinic acid (a stable hydrolyzed metabolite) was used for methylphenidate (an ester drug). The peak area ratio of the unstable metabolites versus the intrinsic stability reference compound was calculated, and the ratios at the testing date were normalized by the first injection or by day 1 measurements for autosampler stability and long-term storage stability evaluations, respectively. Ratio measurements of the drug and metabolite in rat versus human plasma were compared with the nominal ratios, and the errors were stabilized using the geometric mean fold error.
Results
Autosampler Stability. Six unstable substituents and the stable counterparts ( Fig. 1) were selected to test the limitation of the simplified LC-MS/MS methodology described previously. All unstable compounds were detected using the LC-MS/MS methodology described under Materials and Methods. The response ratio of the unstable compound versus the intrinsic stable reference compound collected after overnight injection was compared with the response ratio of the first injection at day 1. If the test metabolite is stable, the ratio of the metabolite versus the intrinsic stability reference compound should be constant and remain as 1 when the ratio is normalized by the response ratio at day 1. Table 2 shows the autosampler stability test results for the six unstable structure substituents after the sample preparations. Both untreated and treated naproxen-naproxen acyl glucuronide conjugates were stable during the overnight injection once the samples were prepared using the acidic workup solution and then reconstituted in acidic solution. Both treated and untreated salicylic acid-2,3-dihydroxybenzoic acid samples, sulfadiazine-N-acetyl sulfadiazine, and nicotine iminium ion-cotinine samples were stable for overnight injection in the temperature-controlled autosampler. Carbamazepine-carbamazepine-10,11-epoxide degraded slightly during the overnight injection. The untreated methylphenidate-ritalinic acid combination samples degraded significantly, whereas the treated samples degraded slower than the untreated samples during the overnight injection.
Long-Term Storage Stability. The long-term storage stability was tested using three independent analyses of the samples covering the storage duration. Without using the synthetic standards, the long-term storage stability of the metabolites was evaluated by comparing the response of the unstable structure versus that of the intrinsic stability reference compound at any test day normalized by the response ratio at day 1. Similar to the autosampler stability test, the response ratio of the metabolite versus the intrinsic stability reference compound should remain constant and will be 1 when normalized by the response ratio at day 1 if the metabolite is stable. The untreated naproxen-naproxen acyl glucuronide conjugate went through migration, whereas the acidified naproxen-naproxen acyl glucuronide conjugate was stable during sample storage and repeated analyses as shown in Fig. 2 . The trend of degradation can be revealed by plotting the response ratio versus the storage time. For example, the treated naproxen-naproxen acyl glucuronide conjugate samples was stable over 130 days stored at Ϫ20°C, whereas the untreated naproxen acyl Fig. 3 . Table 3 lists the test results for six parent-metabolite combinations. The nicotine iminium ion-cotinine combination was not tested because of measurement errors in exposure comparison. Both treated and untreated salicylic acid-2,3-dihydroxybenzoic acid and carbamazepinecarbamazepine-10,11-epoxide were stable over the tested period. Sulfadiazine-N-acetyl sulfadiazine was degraded on the second test and then stabilized after the initial degradation. The treated methylphenidate-ritalinic acid samples were more stable than the untreated samples; however, the intra-assay variability was larger for treated samples, indicating that the treated samples may undergo degradation during the sample preparation.
Comparison of Measured Peak Area Ratios Versus Nominal Ratios Values across Species for Unstable Metabolites.
The ratio of peak areas for each analyte in rat versus human was calculated and compared with the rat versus human concentration ratio calculated from the nominal concentrations. The geometric mean fold errors between measured and nominal ratios assessed on three separate occasions are shown in Fig. 4 . A value of unity reflects perfect agreement between the measured and nominal values. It was shown in our previous work that if the cross-species response ratio is equal to or more than 2, then it can be concluded that the animal has an equivalent or greater exposure to the metabolite (Gao et al., 2010) . Naproxen and its acyl glucuronide were measured both with and without the addition of acid to stabilize the glucuronide. The peak area ratios for acid-treated samples were less than 2 in all cases. For untreated samples, the error in the ratios increased over time such that the error value was greater than 2 on the third analysis (after 130 days stored frozen). This result showed that the peak area ratio method was applicable for acyl glucuronides but only after stabilization with acid.
The analyses of salicylic acid-2,3-dihydroxy benzoic acid, carbamazepine-carbamazepine-10,11-epoxide, and sulfadiazine-N-acetyl sulfadiazine combinations were reproducible with errors Ͻ2.0 in all instances (Fig. 4) . Among them, the salicylic acid-2,3-dihydroxy benzoic acid combination measurements were the most accurate with all three analyses less than 1.17. Measurement errors for ritalinic acid 
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Discussion
Without synthetic standards or radiolabeled material, the stability of metabolites can be tested and established using an intrinsic stability reference. The concept of the stability reference is similar to that of the internal standard in bioanalysis, in which the reference should be in the sample and stored under the same condition as the test metabolites, and its stability should have been demonstrated or well known. In most cases, the parent drug can be used as the stability reference because its stability usually has been tested and established as a part of the validation of its bioanalytical assay. In those cases in which the parent is potentially unstable (e.g., ester) or not suitable as a reference (e.g., the concentration is too high or is changed significantly due to degradation of major metabolites), a stable metabolite (e.g., carboxylic acid for ester) can be used as the stability reference. The parent or a known stable metabolite was in the same samples as the unstable metabolites when the samples were collected; thus, these stability references are truly intrinsic. The response ratio of the test metabolite versus the stability reference should remain constant, and the ratio of the response ratio at any test day versus the day 1 response ratio should be 1, if the metabolite is stable during the storage and sample analysis process.
In the recent European Medicines Agency guideline on bioanalytical method validation (http://www.ema.europa.eu/docs/en_GB/ document_library/Scientific_guideline/2011/08/WC500109686.pdf), stability is evaluated using quality control samples and the mean concentration of each level should be Ϯ15% from the nominal concentrations. For discovery bioanalysis in which the bioanalytical method is not validated, Ϯ20% from the nominal concentrations is deemed accurate (Gao and Obach, 2011) . Therefore, for the peak area ratio approach without the synthetic standard, if the ratio of response ratio at any test day versus the day 1 response ratio is within Ϯ0.2 (or 20%) from 1 (e.g., 0.8 -1.2), the metabolite can be deemed stable. This cutoff can be applied to autosampler stability and long-term storage stability results in Tables 2 and 3 for unstable profile of the ratio of the response ratio at the test day versus day 1 response can also uncover whether the test compound is stable or not; an example is the treated versus untreated naproxen acyl glucuronide conjugate. Much attention should be paid to the trend of the data set to determine whether the degradation occurred during the storage time. Likewise, the autosampler stability can also be tested using the same methodology. In some instances, the unstable metabolite can degrade to the parent drug (e.g., acyl glucuronide conjugate of a carboxylic acid drug hydrolyzing back to the carboxylic acid) and thus not only is the measurement of the peak area ratio for the metabolite inaccurate but also the ratio for the parent drug can be inaccurate, with the degree of inaccuracy dependent on the rate of degradation and the relative concentration of the two entities.
The ratio measurement of metabolites in rat versus human demonstrated that the three independent analyses should be reproducible with good accuracy if the metabolite is stable or is stabilized through established procedures. The measurement error may not increase significantly even if the metabolite is not stable during storage and sample analysis, but only if the rate of degradation is similar in rat and human plasma and the samples were stored at the same time and prepared back to back for LC-MS/MS analysis. This is the case for N-acetyl sulfadiazine and the untreated naproxen acyl glucuronide conjugate for which degradation of the conjugate metabolite during long-term storage was observed; however, the measurement errors for the unstable metabolite did not increase significantly. Of interest, the measurement errors for untreated naproxen increased more than those for the naproxen acyl glucuronide conjugate, especially when the concentrations of the metabolite were much greater than those of the parent because the unstable metabolite degraded to the parent and increased the concentrations for the parent in the samples. This observation is also confirmed in the methylphenidate-ritalinic acid combination, for which the measurement errors for ritalinic acid were larger than those for methylphenidate. This impact is most significant when the concentrations of the unstable metabolite are much more than those of the downstream stable structures. The measurement error for sulfadiazine was larger than that for N-acetyl sulfadiazine when the metabolite concentrations were much higher than those of the parent, although the error for the average cross-species ratio measurements did not increase significantly. Thus, it is important to simultaneously monitor the unstable compound and the downstream stable structure because more measurement errors would be introduced to the stable structure if the conversion takes place during sample storage and analysis. In the case of metabolites that convert to the parent drug, e.g., N-acetyl and glucuronide conjugates, incurred sample reanalysis (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC 2691460/pdf/12248_2009_Article_9100.pdf, http://www.ema.europa. eu/docs/en_GB/document_library/Scientific_guideline/2011/08/ WC500109686.pdf) would uncover the issue and the impact on the parent drug concentration measurements from the metabolite degradation. If the unstable metabolites convert to downstream metabolites without synthetic standards, multiple repetitive analyses of the samples should be executed as described above to assess the impact of degradation; a stable metabolite other than the degraded product can be used as the "intrinsic stability reference." In practice, if the animal samples have been stored longer than the human samples under the same storage condition and the ratio of the metabolites in animal versus human is still larger than 2-fold, that would preclude the false-positive error for the unstable metabolites being due to a stability issue. However, multiple repetitive analyses of the samples will still be needed in the later case.
The simplified LC-MS/MS peak area methodology for relative exposure comparison across species can be applied to most unstable metabolites. Stabilization should be undertaken when the samples are collected, e.g., acidify the acyl glucuronide. The unstable metabolite and the downstream metabolite or structure should be monitored and the impact of the degradation of the unstable metabolite should be evaluated through multiple analyses. In the example of the ester and carboxylic acid pair (i.e., methylphenidate and ritalinic acid), greater error was observed for the carboxylic acid because of hydrolysis of the ester. The error was greater than 2-fold, which was the cutoff value previously demonstrated to offer 99% confidence that the actual ratio was greater than unity. Thus, we conclude that it is unlikely that this method can be used for ester drugs and their carboxylic acid metabolites. However, it should be noted that most carboxylic acid metabolites of ester drugs are accessible by standard synthetic methods; thus, the need to deter- 
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In this study, we have described the application of our previously described LC-MS/MS peak area approach that addresses relative cross-species metabolite exposures to compounds possessing structures prone to chemical-or enzyme-catalyzed instability. Compounds possessing six substituents found in unstable metabolites were selected and tested to establish the limitation of the simple LC-MS/MS methodology for relative exposure comparison across species. The results indicated that the abbreviated LC-MS/MS peak area ratio comparison could be applied to metabolites possessing epoxide, amide, catechol, and acyl glucuronide groups, but it is not suitable for esters and iminium ions. Stability of the suspected unstable metabolites and the degradation impact on downstream metabolites can be assessed using the methodology described in this work. It will be important to further test this approach with more examples of potentially unstable metabolites.
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